Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elritercept + ruxolitinib
- Development stage
- Phase 3
- Lead developer
- Takeda
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
**Elritercept + ruxolitinib** is an investigational combination therapy studied for the treatment of myelofibrosis with anemia. Elritercept (KER-050) is a recombinant fusion protein that consists of a modified activin receptor type-2A extracellular domain fused to an IgG1 Fc, designed to inhibit Activin A/B and other select TGF-β superfamily ligands (including GDF8/11), thus promoting hematopoiesis and improving anemia. Ruxolitinib is an oral small-molecule inhibitor of Janus kinase 1 and 2 (JAK1/2), widely used to reduce spleen size and symptoms in myelofibrosis but often associated with cytopenias. The combination aims to address both ineffective hematopoiesis and the cytopenias (especially anemia) that can be caused or worsened by JAK inhibition. In the RESTORE phase 2 trial, the combination has demonstrated improvements in hemoglobin, transfusion independence, platelet counts, spleen volume, and symptom burden in myelofibrosis patients with anemia.
- Other names
- elritercept + ruxolitinibKER-050 + ruxolitinib
02
Targets
Activin AINHBB (Activin B)GDF11 (Growth differentiation factor 11)GDF8 (Myostatin)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on elritercept + ruxolitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elritercept + ruxolitinib.